| 1.33 0.13 (10.83%) | 03-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.62 |
1-year : | 1.77 |
| Resists | First : | 1.39 |
Second : | 1.51 |
| Pivot price | 1.38  |
|||
| Supports | First : | 1.19 |
Second : | 0.99 |
| MAs | MA(5) : | 1.36 |
MA(20) : | 1.36 |
| MA(100) : | 1.36 |
MA(250) : | 4.38 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 39.4 |
D(3) : | 51.5 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 13.19 | Low : | 1.05 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BIVI ] has closed above bottom band by 28.6%. Bollinger Bands are 26.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.34 - 1.35 | 1.35 - 1.35 |
| Low: | 1.23 - 1.24 | 1.24 - 1.25 |
| Close: | 1.32 - 1.33 | 1.33 - 1.34 |
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Sun, 22 Mar 2026
If You Invested $1,000 in Biovie Inc (BIVI) - Stock Titan
Wed, 18 Mar 2026
BIVI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Thu, 12 Mar 2026
BioVie to present Parkinson’s study data at AD/PD 2026 conference - Proactive financial news
Thu, 12 Mar 2026
Parkinson’s trial drug heads to 2026 Alzheimer’s & Parkinson’s meeting - Stock Titan
Mon, 02 Mar 2026
Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI) - The Wall Street Transcript
Wed, 11 Feb 2026
BioVie could offer first new Parkinson’s therapy in decades - Proactive financial news
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 19 (%) |
| Shares Short | 178 (K) |
| Shares Short P.Month | 153 (K) |
| EPS | -3.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.3 % |
| Return on Equity (ttm) | -80.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.41 |
| PEG Ratio | 0 |
| Price to Book value | 0.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|